Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 951 - 975 of 15281 in total

Posaconazole

Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Approved
Investigational
Vet approved
Matched Description: … Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and …
Matched Categories: … Triazole and tetrazole derivatives ... Metabolic Side Effects of Drugs and Substances ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Adalimumab

Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and ... [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. ... was approved in July 2022 -,[L42495] adalimumab-bwwd - which was approved in August 2022 -,[L42935] and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Clemastine

An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Approved
Investigational
Matched Description: … ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and …

Beroctocog alfa

Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins …

Belzutifan

Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. Initially considered to be undruggable,...
Approved
Investigational
Matched Description: … binding pocket was eventually discovered in the HIF-2α molecule which allowed for compounds to bind and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Dolichovespula arenaria venom protein

Dolichovespula arenaria venom protein is an extract of Dolichovespula arenaria venom. Dolichovespula arenaria venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Vespula vulgaris venom protein

Vespula vulgaris venom protein is an extract of Vespula vulgaris venom. Vespula vulgaris venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Carbon monoxide

Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that has a slightly lower density than air. It is toxic to hemoglobin utilizing animals (including humans), when encountered in concentrations above about 35 ppm, although it is also formed in normal animal metabolism in low quantities, and is thought...
Approved
Investigational
Matched Description: … inflammatory diseases of the lung and other organs. ... The DLCO test is both convenient and simple for the patient to undergo. ... Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that has a slightly lower density than …

Guanadrel

Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
Approved
Matched Description: … Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. …

Cyclobenzaprine

Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from Amitriptyline by only a single double bond.[A185039,A184982] Since its approval, it has...
Approved
Matched Description: … Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been …

Osilodrostat

Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's...
Approved
Investigational
Matched Description: … Cushing's disease),[A191850] and was granted FDA approval and Orphan Drug designation in the US in March ... Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical ... L12123] It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and …
Matched Categories: … Sex Hormones and Insulins …

Oxolamine

Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant . It is listed as a prescription drug in New Zealand legislation . Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation .
Approved
Matched Categories: … Cough and Cold Preparations …

Amoxapine

Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation....
Approved
Matched Description: … , and mixed symptoms of depression and anxiety or agitation. ... Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression ... TCAs are potent inhibitors of serotonin and norepinephrine reuptake. …

Brigatinib

Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a...
Approved
Investigational
Matched Description: … Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and ... Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Penbutolol

Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the...
Approved
Investigational
Matched Description: … Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker ... degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity. ... Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third …
Matched Categories: … penbutolol and other diuretics …

Secnidazole

Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including DB00916 and DB00911, but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once...
Approved
Matched Description: … to form a radical anion, thereby damaging and killing the target pathogen. ... It is structurally related to other 5-nitroimidazoles, including [DB00916] and [DB00911], but displays ... improved oral absorption and a longer terminal elimination half-life than other drugs in this class. …
Matched Categories: … azithromycin, fluconazole and secnidazole ... Antiparasitic Products, Insecticides and Repellents …

Pralsetinib

Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Rotigotine

Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours....
Approved
Matched Description: … restless legs syndrome (RLS) in Europe and the United States. ... It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. ... (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and …

Larotrectinib

Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and...
Approved
Investigational
Matched Description: … plays an important role in tumor cell growth and survival. ... receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and ... Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Lorpiprazole

Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Approved
Matched Description: … Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive …

Osimertinib

Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs ... [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Abemaciclib

Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Description: … Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6 ... ) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity ... granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tovorafenib

Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation,...
Approved
Investigational
Matched Description: … growth and survival. ... [A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell ... [L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation …

Elranatamab

Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific...
Approved
Investigational
Matched Description: … immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and ... an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one light chain to drug structure …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Idelalisib

Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab...
Approved
Matched Description: … (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils ... signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and ... type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 951 - 975 of 15281 in total